Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age. We studied functional replacement of the mutated gene encoding survival motor neuron 1 (SMN1) in this disease. METHODS: vg per kilogram). The primary outcome was safety. The secondary outcome was the time until death or the need for permanent ventilatory assistance. In exploratory analyses, we compared scores on the CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scale of motor function (ranging from 0 to 64, with higher scores indicating better function) in the two cohorts and motor milestones in the high-dose cohort with scores in studies of the natural history of the disease (historical cohorts). RESULTS: As of the data cutoff on August 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared with a rate of survival of 8% in a historical cohort. In the high-dose cohort, a rapid increase from baseline in the score on the CHOP INTEND scale followed gene delivery, with an increase of 9.8 points at 1 month and 15.4 points at 3 months, as compared with a decline in this score in a historical cohort. Of the 12 patients who had received the high dose, 11 sat unassisted, 9 rolled over, 11 fed orally and could speak, and 2 walked independently. Elevated serum aminotransferase levels occurred in 4 patients and were attenuated by prednisolone. CONCLUSIONS: In patients with SMA1, a single intravenous infusion of adeno-associated viral vector containing DNA coding for SMN resulted in longer survival, superior achievement of motor milestones, and better motor function than in historical cohorts. Further studies are necessary to confirm the safety and efficacy of this gene therapy. (Funded by AveXis and others; ClinicalTrials.gov number, NCT02122952 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, the FDA has approved AAV for gene replacement therapy in spinal muscular atrophy and congenital blindness, and clinical trials are in progress 58 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [58]
In the citing paper
“preclinical and clinical studies have demonstrated dose-dependent inflammation, which can reduce efficacy and lead to dose-limiting toxicity (2–8)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [4]
In the citing paper
“Although neuroimaging is typically more expensive than EEG and studies are limited by issues of replication, sometimes that is related to head motion that occurred during the scan which can erode signal 61”
From Autism spectrum disorder (2020) · cites this paper as [61]
In the citing paper
“Especially considering the ability of the recombinant AAV genome to persist as an episome in post-mitotic cells, such as neurons, which ensures long-term expression even after a single administration [130-132].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [132]
In the citing paper
“With AAV9’s inherent ability to target motor neurons, AAV9-based Zolgensma® for the treatment of SMA has been established as the first FDA-approved drug for systemic gene therapy in CNS diseases [171].”
From Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside (2024) · cites this paper as [171]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
Self-citationRetractedDeaths: preliminary data for 2003.
Hoyert, D. L., Kung, H.-C., & Smith, B. L. (2005) · PubMed · Cited by 1,649
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Self-citationBayley Scales of Infant and Toddler Development, Third Edition
Bayley, N. (2012) · PsycTESTS Dataset · doi:10.1037/t14978-000 · Cited by 1,175
National Vital Statistics Reports NCHS.pdf
Hoyert, D. (2012) · Medical Entomology and Zoology · Cited by 982
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961 · cited 4×
“Viral upper respiratory tract infection 0 0 3 3 (25) 3 3 (20)”
InfluentialAntisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664
Sugarman, E. A., Nagan, N., Zhu, H., Akmaev, V. R., Zhou, Z., Rohlfs, E. M., Flynn, K., Hendrickson, B. C., Scholl, T., Sirko-Osadsa, D. A., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.134 · Cited by 661
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
de Onis, M., Onyango, A. W., Van den Broeck, J., Chumlea, W. C., & Martorell, R. (2004) · Food and Nutrition Bulletin · doi:10.1177/15648265040251s105 · Cited by 529
Research works printed but not linked: 1
- Hoyert DL, 2012, Natl Vital Stat Rep, 61, 1
Cited by
Items 801–900 of 1,005
Zhang, X., Chai, Z., Lee Dobbins, A., Itano, M. S., Askew, C., Miao, Z., Niu, H., Samulski, R. J., & Li, C. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121340 · Cited by 23
Recent developments of automated flow chemistry in pharmaceutical compounds synthesis
Wu, J., Yang, X., Pan, Y., Zuo, T., Ning, Z., Li, C., & Zhang, Z. (2023) · Journal of Flow Chemistry · doi:10.1007/s41981-023-00285-x · Cited by 28
Hatanaka, F., Suzuki, K., Shojima, K., Yu, J., Takahashi, Y., Sakamoto, A., Prieto, J., Shokhirev, M. N., Núñez‐Delicado, E., Esteban, C. R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50095-5 · Cited by 26
Chauhan, M., Daugherty, A. L., Khadir, F., Duzenli, O. F., Hoffman, A., Tinklenberg, J. A., Kang, P. B., Aslanidi, G., & Pacak, C. A. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05599-5 · Cited by 27
“We are particularly keen to avoid the liver as AAVs that are delivered systemically tend to be sequestered in the liver [22, 23] This leads to reduced transduction of target (non-liver) organs and potentially liver toxicity [24, 25], which may in some cases be fatal [26].”
BackgroundNeurological glycogen storage diseases and emerging therapeutics
Colpaert, M. G., Singh, P. K., Donohue, K. J., Pires, N. T., Fuller, D. D., Corti, M., Byrne, B. J., Sun, R. C., Kooi, C. W. V., & Gentry, M. S. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00446 · Cited by 27
“Two rAAV-based therapies recently received FDA approval, Lux-turna for inherited retinal dystrophy and Zolegensma for spinal muscular atrophy [227,228].”
Porcari, G. S., Collyer, J. W., Adang, L. A., & Rajan, D. S. (2025) · Neurology Genetics · doi:10.1212/nxg.0000000000200229 · Cited by 31
Borges, B., Brown, S. M., Chen, W., Clarke, M. T., Herzeg, A., Park, J. H., Ross, J., Kong, L., Denton, M., Smith, A. K., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adv4656 · Cited by 24
AAV9-Mediated Gene Therapy for Infantile-Onset Pompe’s Disease
Ma, X., Zhuang, L., Ma, W., Li, J., Mao, Y., Wang, J., Wang, X., Xu, J., Yu, S., Gu, R., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2407766 · Cited by 25
Flotte, T. R., & Büning, H. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.021 · Cited by 26
Viral gene therapy for paediatric neurological diseases: progress to clinical reality
Privolizzi, R., Chu, W. S., Tijani, M., & Ng, J. (2021) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14885 · Cited by 21
“7910(13)vg 2910(14) vg Intravenous NCT02122952; Mendell et al.(8) 2014–2017”
BackgroundInfluentialHensel, N., Cieri, F., Santonicola, P., Tapken, I., Schüning, T., Taiana, M. M., Pagliari, E., Joseph, A., Fischer, S., Heidrich, N., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2007785118 · Cited by 23
“Onasemnogene Abeparvovec is a gene-therapy based on the delivery of a SMN cDNA by an adeno-associated virus (AAV) (9, 10).”
BackgroundLee, B. H., Waldrop, M. A., Connolly, A. M., & Ciafaloni, E. (2021) · Muscle & Nerve · doi:10.1002/mus.27261 · Cited by 23
“SMN1 gene replacement with onasemnogene abeparvovec-xioi (Zolgensma; AveXis, Inc, Bannockburn, Illinois, hereafter referred to as onasemnogene) received US Food and Drug Administration (FDA) approval in May 2019 after demonstrating superior motor outcomes compared with the wellestablished natural history.(2) Furthermo…”
BackgroundCRISPR-derived genome editing therapies: Progress from bench to bedside
Rees, H. A., Minella, A. C., Burnett, C. A., Komor, A. C., & Gaudelli, N. M. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.027 · Cited by 26
Kuwayama, R., Suzuki, K., Nakamura, J., Aizawa, E., Yoshioka, Y., Ikawa, M., Nabatame, S., Inoue, K., Shimmyo, Y., Ozono, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30847-x · Cited by 27
Paul, A., Collins, M. G., & Lee, H. Y. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.899209 · Cited by 27
Elkins, K., Wittenauer, A., Hagar, A. F., Logan, R., Sekul, E. A., Xiang, Y., Verma, S., & Wilcox, W. R. (2022) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.32003 · Cited by 23
PCR-Based Screening of Spinal Muscular Atrophy for Newborn Infants in Hyogo Prefecture, Japan
Noguchi, Y., Bo, R., Nishio, H., Matsumoto, H., Matsui, K., Yano, Y., Sugawara, M., Ueda, G., Wijaya, Y. O. S., Niba, E. T. E., et al. (2022) · Genes · doi:10.3390/genes13112110 · Cited by 24
Prospects for gene replacement therapies in amyotrophic lateral sclerosis
Giovannelli, I., Higginbottom, A., Kirby, J., Azzouz, M., & Shaw, P. J. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00751-5 · Cited by 25
A Unified Model of Age-Related Cardiovascular Disease
Fossel, M., Bean, J., Khera, N., & Kolonin, M. G. (2022) · Biology · doi:10.3390/biology11121768 · Cited by 26
Barrois, R., Barnérias, C., Deladrière, E., Leloup-Germa, V., Tervil, B., Audic, F., Boulay, C., Cancés, C., Cintas, P., Davion, J., et al. (2023) · Neuromuscular Disorders · doi:10.1016/j.nmd.2023.02.004 · Cited by 24
Westhaus, A., Cabanes‐Creus, M., Dilworth, K. L., Zhu, E., Gómez, D. S., Navarro, R. G., Amaya, A. K., Scott, S., Kwiatek, M., McCorkindale, A. L., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.188 · Cited by 25
Lu, M., Lee, Z., Lin, Y., Irfanullah, I., Cai, W., & Hu, W. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28562 · Cited by 26
Ruggiero, R., Balzano, N., Nicoletti, M. M., di Mauro, G., Fraenza, F., Campitiello, M. R., Rossi, F., & Capuano, A. (2024) · Pharmaceuticals · doi:10.3390/ph17030394 · Cited by 26
“This one-shot and lifetime gene replacement therapy directly works on the monogenic cause of SMA [11].”
BackgroundChai, Z., Zhang, X., Dobbins, A., Rigsbee, K. M., Wang, B., Samulski, R., & Li, C.-W. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.233 · Cited by 22
“Glucocorticoids have been proposed to be included in regimens for the systemic administration of AAV vectors in patients with CNS and muscular disorders.(34) In addition to its modulation of the immune system, glucocorticoids are also widely used in clinics to retain vascular permeability in patients with inflammation…”
BackgroundNext Generation of Adeno-Associated Virus Vectors for Gene Therapy for Human Liver Diseases
Berns, K. I., & Srivastava, A. (2019) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.02.005 · Cited by 23
Kanao-Kanda, M., Kanda, H., Liu, S., Roy, S., Toborek, M. J., & Hao, S. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.359 · Cited by 23
“Recent CNS clinical trials show that AAV vectors have been used for single gene genetic disorders, such as spinal muscular atrophy and giant axon neuropathy.(64,65) An AAV vector was constructed using the AAV helper-free system to express GAD65.”
MethodImpact of a national population-based carrier-screening program on spinal muscular atrophy births
Aharoni, S., Nevo, Y., Orenstein, N., Basel‐Salmon, L., Ben‐Shachar, S., Mussaffi, H., Sagi‐Dain, L., Cohen, R., & Singer, A. (2020) · Neuromuscular Disorders · doi:10.1016/j.nmd.2020.10.005 · Cited by 23
R-Roscovitine Improves Motoneuron Function in Mouse Models for Spinal Muscular Atrophy
Tejero, R., Balk, S., Franco-Espín, J., Ojeda, J., Hennlein, L., Drexl, H., Dombert, B., Clausen, J.-D., Torres‐Benito, L., Saal-Bauernschubert, L., et al. (2020) · iScience · doi:10.1016/j.isci.2020.100826 · Cited by 26
Rimoldi, M., Lucchiari, S., Pagliarani, S., Meola, G., Comi, G. P., & Abati, E. (2024) · Neurological Sciences · doi:10.1007/s10072-024-07826-9 · Cited by 27
“AAV serotype 9 (AAV9), isolated from human liver tissue, was proved to be able to reach the MNs of the spinal cord, the cortical neurons and the deep structures of the brain, due to its unique ability to cross the blood-brain barrier [120 – 123].”
Engineering strategies of sequential drug delivery systems for combination tumor immunotherapy
Xu, Z., Liu, S., Li, Y., Wu, Y., Tu, J., Chen, Q., & Sun, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.05.039 · Cited by 33
“Currently, gene-immunotherapy as a standalone treatment is not effective enough, which may be related to the fact that the window of effectiveness concentration is not enough 185 .”
Barrett, D., Cannon, P. M., Mingozzi, F., Porteus, M. H., Rivière, I., & Flotte, T. R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.049 · Cited by 24
Carraro, U. (2020) · European Journal of Translational Myology · doi:10.4081/ejtm.2019.8826 · Cited by 22
Targeting the 5′ untranslated region of SMN2 as a therapeutic strategy for spinal muscular atrophy
Winkelsas, A. M., Grunseich, C., Harmison, G. G., Chwalenia, K., Rinaldi, C., Hammond, S. M., Johnson, K. R., Bowerman, M., Arya, S., Talbot, K., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.12.027 · Cited by 24
Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment
Tan, Z., Chiu, M. S., Yan, C. W., Man, K., & Chen, Z. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.01.010 · Cited by 22
Hamm, S. E., Fathalikhani, D. D., Bukovec, K. E., Addington, A. K., Zhang, H., Perry, J. B., McMillan, R. P., Lawlor, M. W., Prom, M. J., Avond, M. A. V., et al. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.024 · Cited by 26
Slayter, J., Hodgkinson, V. L., Lounsberry, J., Brais, B., Chapman, K. M., Genge, A. L., Izenberg, A., Johnston, W. S. W., Lochmüller, H., O’Ferrall, E., et al. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-200617 · Cited by 28
“Recently, there have been significant advancements in SMA treatments which utilize therapeutic mechanisms such as SMN1 gene replacement via viral vectors [5], synthetic olignoucleotides and small molecules which encourage production of SMN1 protein via altered SMN2 splicing [6, 7], neuroprotection, and enhancement of…”
BackgroundSpinal muscular atrophy: state of the art and new therapeutic strategies
Messina, S., Sframeli, M., Maggi, L., D’Amico, A., Bruno, C., Comi, G. P., & Mercuri, E. M. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05258-3 · Cited by 24
“4 points at 3 months of the CHOP INTEND scale score compared to the decrease observed in the historical cohort; furthermore, 11 patients reached the ability to sit unassisted, 9 were able to roll over, and 2 walked independently [15].”
Nuclear-Import Receptors Counter Deleterious Phase Transitions in Neurodegenerative Disease
Odeh, H. M., Fare, C. M., & Shorter, J. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167220 · Cited by 26
Hakui, H., Kioka, H., Miyashita, Y., Nishimura, S., Matsuoka, K., Kato, H., Tsukamoto, O., Kuramoto, Y., Takuwa, A., Takahashi, Y., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abf3274 · Cited by 25
A Comparison of Caregiver and Patient Preferences for Treating Duchenne Muscular Dystrophy
Crossnohere, N. L., Fischer, R. A., Vroom, E., Furlong, P., & Bridges, J. F. P. (2022) · Patient · doi:10.1007/s40271-022-00574-y · Cited by 26
Wang, T., Scuffham, P., Byrnes, J., & Downes, M. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11319-0 · Cited by 24
Investigating attitudes toward prenatal diagnosis and fetal therapy for spinal muscular atrophy
Schwab, M. E., Shao, S. J., Zhang, L., Lianoglou, B. R., Belter, L. T., Jarecki, J., Schroth, M. K., Sumner, C. J., & MacKenzie, T. C. (2022) · Prenatal Diagnosis · doi:10.1002/pd.6228 · Cited by 22
Herzeg, A., Almeida-Porada, G. D., Charo, R. A., David, A. L., Gonzalez‐Velez, J. M., Gupta, N. M., Lapteva, L., Lianoglou, B. R., Peranteau, W. H., Porada, C. D., et al. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2127 · Cited by 28
Flexible endoscopic evaluation of swallowing in children with type 1 spinal muscular atrophy
Zang, J., Johannsen, J., Denecke, J., Weiss, D., Koseki, J., Niessen, A. C., Müller, F., Nienstedt, J. C., Flügel, T., & Pflug, C. (2022) · European Archives of Oto-Rhino-Laryngology · doi:10.1007/s00405-022-07685-0 · Cited by 22
Salimando, G. J., Tremblay, S., Kimmey, B. A., Li, J., Rogers, S. A., Wojick, J. A., McCall, N. M., Wooldridge, L. M., Rodrigues, A., Borner, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41407-2 · Cited by 20
“…associated with AAV-based vectors 15,96 and recent successes in the application of AAV-based therapeutics to treat several patient populations 97,98 , further translationally minded studies could explore the utility of construct design schemas focused on targeting distinct elements identi fi…”
Qiao, Y., Chi, Y., Gu, J., & Ma, Y. (2023) · Brain Sciences · doi:10.3390/brainsci13101419 · Cited by 29
“Later, another gene replacement therapy named zolgensma (onasemnogene, AVXS-101), which delivers the SMN1 gene to motor neurons and produces full-length functional SMN protein through the adeno-associated virus (AAV), was approved by the FDA in May 2019 [14,15].”
2014 Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression
Galanopoulou, A. S., Wong, M., Binder, D. K., Hartman, A. L., Powell, E. M., Roopra, A., Staba, R. J., Vezzani, A., Fureman, B. E., & Dingledine, R. J. (2016) · Epiliepsy currents/Epilepsy currents · doi:10.5698/1535-7511-16.3.187 · Cited by 21
New Developments in the Genetics of Inclusion Body Myositis
Britson, K. A., Yang, S. Y., & Lloyd, T. E. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0738-0 · Cited by 22
Shen, X., Xu, Y., Bai, Z., Ma, D., Niu, Q., Meng, J., Fan, S., Zhang, L., Hao, Z., Zhang, X., et al. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2018.148 · Cited by 25
The path from scientific discovery to cures for epilepsy
Carvill, G. L., Dulla, C. G., Lowenstein, D. H., & Brooks‐Kayal, A. R. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107702 · Cited by 23
Viral vectors for neuronal cell type-specific visualization and manipulations
Liu, Y., Hegarty, S. V., Winter, C. C., Wang, F., & He, Z. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.03.011 · Cited by 23
Efficacy and costs of spinal muscular atrophy drugs
Darrow, J. J., Sharma, M., Shroff, M., & Wagner, A. K. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay9648 · Cited by 23
Pathogenesis and therapeutic targets in spinal muscular atrophy (SMA)
Lefebvre, S., & Sarret, C. (2020) · Archives de Pédiatrie · doi:10.1016/s0929-693x(20)30269-4 · Cited by 30
Novel genome-editing-based approaches to treat motor neuron diseases: Promises and challenges
Miccio, A., Antoniou, P., Ciura, S., & Kabashi, E. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.04.003 · Cited by 21
Suriano, C. M., Kumar, N., Verpeut, J. L., Ma, J., Jung, C., Dunn, C. E., Carvajal, B. V., Nguyen, A. V., & Boulanger, L. M. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.03.036 · Cited by 21
“…clinically to restore endogenous protein function in the nervous system to treat Leber ’ s congenital amaurosis 2 2,3 and spinal muscular atrophy, 4,5 and AAV-based clinical trials are under way to treat numerous other disorders of the nervous system, including Alzheimer ’ s disease, Canavan ’ s…”
Novel approaches to increase synaptic resilience as potential treatments for Alzheimer’s disease
Pham, A. Q., & Dore, K. (2023) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2022.03.032 · Cited by 21
Martin, T. P., MacDonald, E. A., Bradley, A., Watson, H. H., Saxena, P., Rog‐Zielinska, E. A., Raheem, A., Fisher, S., Elbassioni, A. A. M., Almuzaini, O., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad107 · Cited by 26
“30 AAV9 encoding shRNA provides highly efficient knockdown in the heart.”
BackgroundArora, R., & Baldi, A. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128284824240328071911 · Cited by 28
Drug‐induced liver injury related to gene therapy: A new challenge to be managed
Larrey, D. G., Delire, B., Meunier, L., Zahhaf, A., Martin, E. D., & Horsmans, Y. (2024) · Liver International · doi:10.1111/liv.16065 · Cited by 26
“19,20 In two patients, liver injury was severe with elevation of bilirubin 2–7 weeks after initiation of therapy, but both patients responded to corticosteroid treatment.”
Khayrullina, G., Moritz, K. E., Schooley, J. F., Fatima, N., Viollet, C., McCormack, N. M., Smyth, J. T., Doughty, M. L., Dalgard, C. L., Flagg, T. P., et al. (2020) · Skeletal Muscle · doi:10.1186/s13395-020-00232-7 · Cited by 21
“Recently, therapeutic breakthroughs, genereplacement therapy using viral delivery [3] and altering SMN2 splicing using antisense oligonucleotides [4], have remarkably improved motor function and survival of SMA patients, but patients remain prone to cardiopulmonary complications leading to opportunistic upper respirat…”
BackgroundBuscara, L., Gross, D., & Danièle, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040258 · Cited by 23
“Thus, the therapeutic window is probably quite narrow in the SMA trial, as high levels of vector are necessary to achieve therapeutic benefit.”
BackgroundInfluentialSelecting disease‐modifying medications in 5q spinal muscular atrophy
Cartwright, M. S., & Upadhya, S. (2021) · Muscle & Nerve · doi:10.1002/mus.27358 · Cited by 22
“Onasemnogene abeparvovecxioi is approved for individuals less than 24 months of age.(13) Risdiplam is a small molecule splicing modifier.”
BackgroundAbulimiti, A., Lai, M. S., & Chang, R. C. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111549 · Cited by 23
Chong, L. C., Gandhi, G., Lee, J. M., Yeo, W. W. Y., & Choi, S. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168962 · Cited by 26
Axonal excitability changes in children with spinal muscular atrophy treated with nusinersen
Kariyawasam, D. S. T., D’Silva, A., Herbert, K., Howells, J., Carey, K. A., Kandula, T., Farrar, M. A., & Lin, C. S.-Y. (2021) · The Journal of Physiology · doi:10.1113/jp282249 · Cited by 23
Zhou, W., Yang, J., Zhang, Y., Hu, X., & Wang, W. (2022) · MedComm · doi:10.1002/mco2.155 · Cited by 31
Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy
Errico, F., Marino, C., Grimaldi, M., Nuzzo, T., Bassareo, V., Valsecchi, V., Panicucci, C., Schiavi, E. D., Mazza, T., Bruno, C., et al. (2022) · Biomolecules · doi:10.3390/biom12101431 · Cited by 26
Al-Naimi, A. R., Hamad, S. G., Mohamed, R., Ben‐Omran, T., Ibrahim, K. O., Osman, M. F. E., & Abu‐Hasan, M. (2022) · Pediatric Pulmonology · doi:10.1002/ppul.26285 · Cited by 20
“GRT induces SMN expression in motor neurons and peripheral tissues leading to improved SMN protein production and survival.(15) GRT was shown to result in significant clinical benefits compared with historical data in terms of improvement in muscle strength, slowing of disease progression and improvement in overall su…”
BackgroundGene therapies for mucopolysaccharidoses
Rossi, A., & Brunetti‐Pierri, N. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12626 · Cited by 25
“47 Zolgensma, for GT of SMA, received approval as the first systemically delivered AAV-based GT in May 2019 (first approved AAV-based GTs were: Glybera, for intramuscular injections in lipoprotein lipase deficiency, later withdrawn from the market, and Luxutrna, for sub-retinal injections in RPE65…”
BackgroundRizzo, F., Bono, S., Ruepp, M., Salani, S., Ottoboni, L., Abati, E., Melzi, V., Cordiglieri, C., Pagliarani, S., Gioia, R. D., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-05018-w · Cited by 28
Reilly, A., Yaworski, R., Beauvais, A., Schneider, B. L., & Kothary, R. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad202 · Cited by 22
Vill, K., Tacke, M., König, A., Baumann, M., Baumgärtner, M., Steinbach, M., Bernert, G., Blaschek, A., Deschauer, M., Flotats‐Bastardas, M., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12188-5 · Cited by 24
Strategies for enhanced gene delivery to the central nervous system
Gao, Z. (2024) · Nanoscale Advances · doi:10.1039/d3na01125a · Cited by 29
Basche, M., Kampik, D., Kawasaki, S., Branch, M. J., Robinson, M. R., Larkin, F., Smith, A. J., & Ali, R. R. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.115 · Cited by 23
“51 We therefore examined the potential corneal application of this route of administration in more detail, specifically with regard to the corneal epithelium and LESCs.”
Intravenous delivery of adeno-associated viral gene therapy in feline GM1 gangliosidosis
Gross, A. L., Gray‐Edwards, H. L., Bebout, C. N., Ta, N. L., Nielsen, K., Brunson, B. L., Mercado, K. R. L., Osterhoudt, D. E., Batista, A. R., Maitland, S. A., et al. (2021) · Brain · doi:10.1093/brain/awab309 · Cited by 21
Kotterman, M., Beliakoff, G., Croze, R., Vazin, T., Schmitt, C., Szymanski, P., Leong, M., Quezada, M., Holt, J., Barglow, K., et al. (2021) · doi:10.1101/2021.06.24.449775 · Cited by 20
Engineering novel adeno-associated viruses (AAVs) for improved delivery in the nervous system
Carneiro, A. D., & Schaffer, D. V. (2024) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2024.102532 · Cited by 22
Álvarez, K., Suárez, B., Palomino, M. A., Hervias, C., Calcagno, G., Martínez-Jalilie, M., Lozano‐Arango, A., Lillo, S., Haro, M., Cortés, F. M., et al. (2019) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20190073 · Cited by 26
Neuromuscular Diseases of the Newborn
Fay, A. J. (2019) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2019.08.007 · Cited by 21
Huang, Y., Huang, W., Huang, Y., Song, P., Zhang, M., Zhang, H., Pan, S., & Hu, Y. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191098 · Cited by 22
High rate of HDR in gene editing of p.(Thr158Met) MECP2 mutational hotspot
Croci, S., Carriero, M., Capitani, K., Daga, S., Donati, F., Frullanti, E., Lamacchia, V., Tita, R., Giliberti, A., Valentino, F., et al. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-020-0624-x · Cited by 22
“Indel frequency: percentage of insertions and deletions caused by Cas9 activity; C (WT): wild type nucleotide; T (M): mutated nucleotide Gene therapy using a gene replacement approach, as the one recently tested in patients affected by SMA [33], has been extensively tested in RTT mouse models but has resulted in toxic…”
BackgroundInfluentialA Crucial Role for the Protein Quality Control System in Motor Neuron Diseases
Cristofani, R., Crippa, V., Cicardi, M. E., Tedesco, B., Ferrari, V., Chierichetti, M., Casarotto, E., Piccolella, M., Messi, E., Galbiati, M., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00191 · Cited by 28
POLR3-Related Leukodystrophy: Exploring Potential Therapeutic Approaches
Perrier, S., Michell‐Robinson, M. A., & Bernard, G. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.631802 · Cited by 25
Delivery of Nusinersen Through an Ommaya Reservoir in Spinal Muscular Atrophy
Iannaccone, S. T., Paul, D. J., Castro, D., Weprin, B. E., & Swift, D. M. (2021) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0000000000000333 · Cited by 21
MCOLN1 gene therapy corrects neurologic dysfunction in the mouse model of mucolipidosis IV
DeRosa, S., Salani, M., Smith, S., Sangster, M., Miller-Browne, V., Wassmer, S., Xiao, R., Vandenberghe, L. H., Slaugenhaupt, S. A., Misko, A. L., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab093 · Cited by 17
Querin, G., Biferi, M. G., & Pradat, P. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-210754 · Cited by 24
“Importantly, clinical trials for gene targeting strategies in other diseases demonstrated the importance of precocious therapeutic interventions (Zolgensma) [29].”
BackgroundNon-Viral Delivery of RNA Gene Therapy to the Central Nervous System
Hauck, E. S., & Hecker, J. G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010165 · Cited by 28
“Two years after treatment, all 15 patients were alive and event free compared to the 8% survival of an historical cohort [57].”
BackgroundBalaji, L., Farrar, M. A., D’Silva, A., & Kariyawasam, D. S. T. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2218549 · Cited by 27
“Recent technological advances including long-read DNA and RNA sequencing methodologies allow for the increasingly detailed analysis of the structure, sequence and expression of the highly complex SMN locus.”
MethodSystemic gene therapy rescues retinal dysfunction and hearing loss in a model of Norrie disease
Pauzuolyte, V., Patel, A., Wawrzynski, J. R., Ingham, N. J., Leong, Y. C., Karda, R., Bitner-Glindzicz, M. A. K., Berger, W., Waddington, S. N., Steel, K. P., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202317393 · Cited by 22
“AAV9 has been shown to cross the blood – brain barrier (Merkel et al , 2017) and transduce a broad range of cells, including in the retina and cochlea (Shibata et al , 2017; Massaro et al , 2020), and is already approved for clinical use (Mendell et al , 2017; Strauss et al , 2022).”
BackgroundTowards personalized therapies for genetic disorders of surfactant dysfunction
de Nieuwburgh, M. P., Wambach, J., Griese, M., & Danhaive, O. (2023) · Seminars in Fetal and Neonatal Medicine · doi:10.1016/j.siny.2023.101500 · Cited by 26
Molecular mechanisms and therapeutic strategies for neuromuscular diseases
Zambon, A. A., Falzone, Y., Bolino, A., & Previtali, S. C. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05229-9 · Cited by 26
“The global prevalence is approximately 1:10.000 individuals, making SMA among the more frequent neuromuscular disorders.”
BackgroundInfluentialLi, Y., Li, J., Liu, Y., Shi, Z., Liu, H., Wei, Y., & Yang, L. (2019) · Gene Therapy · doi:10.1038/s41434-019-0081-8 · Cited by 21
Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy
McCall, A. L., Stankov, S. G., Cowen, G., Cloutier, D., Zhang, Z., Yang, L., Clement, N., Falk, D. J., & Byrne, B. J. (2019) · Current Gene Therapy · doi:10.2174/1566523219666190621113807 · Cited by 21
Astrocytes in Motor Neuron Diseases
Valori, C. F., Guidotti, G., Brambilla, L., & Rossi, D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-9913-8_10 · Cited by 22
Geographic and Specialty Access Disparities in US Pediatric Leukodystrophy Diagnosis
Grineski, S. E., Morales, D. X., Collins, T. W., Wilkes, J., & Bonkowsky, J. L. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.01.063 · Cited by 21
Mitochondrial diseases: expanding the diagnosis in the era of genetic testing
Saneto, R. P. (2020) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2020.40 · Cited by 22
“Genetic treatment of disease has recently entered the clinical realm as the Federal Drug Agency (FDA) approved the use of a single dose of intravenous adeno-associated virus serotype 9 carrying human survival motor neuron gene (SMN) complementary DNA for patients with spinal motor atrophy([367]).”
BackgroundSpaull, R., Soo, A. K. S., Hogarth, P., Hayflick, S. J., & Kurian, M. A. (2021) · Tremor and Other Hyperkinetic Movements · doi:10.5334/tohm.661 · Cited by 24
Base editing as a genetic treatment for spinal muscular atrophyPreprint
Alves, C. R. R., Ha, L. L., Yaworski, R., Lazzarotto, C. R., Christie, K. A., Reilly, A., Beauvais, A., Doll, R. M., de la Cruz, D., Maguire, C. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.20.524978 · Cited by 20
“…addition using an adeno-associated virus (AAV) vector expressing SMN1 such as onasemnogene abeparvovec (Zolgensma, Novartis) presents many challenges 19 , including unknown longevity of expression from the AAV transgene 20 , and eventual decay of efficacy in dividing cells due to AAV dilution 21 .”
Mich, J. K., Sunil, S., Johansen, N., Martinez, R. A., Liu, J., Gore, B. B., Mahoney, J. T., Leytze, M., Ben‐Simon, Y., Bertagnolli, D., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.20.558718 · Cited by 22
Chongmelaxme, B., Yodsurang, V., Vichayachaipat, P., Srimatimanon, T., & Sanmaneechai, O. (2024) · Gene Therapy · doi:10.1038/s41434-024-00503-8 · Cited by 27
“Among the 57 studies, 20 were excluded from the meta-analysis due to variations in participant characteristics [11, 12, 24, 25, 28, 35, 39, 40, 43, 52 – 54, 58, 63, 67], gene-based interventions, [33, 58] and outcome assessments [42, 57, 68].”
Metadata
- Authors
- Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J. T., Nagendran, S., L’Italien, J., Sproule, D. M., Wells, C., Cardenas, J. A., Heitzer, M. D., Kaspar, A., Corcoran, S., Braun, L., Likhite, S., Miranda, C., Meyer, K., Foust, K. D., Burghes, A. H. M., & Kaspar, B. K.
- Affiliations
- Abigail Wexner Research Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-02
- Volume
- 377
- Issue
- 18
- Pages
- 1713-1722
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2765253110
- Cited by
- 2,381
- References
- 26
- Citations by year
- 2026: 205 · 2025: 232 · 2024: 292 · 2023: 270 · 2022: 289 · 2021: 347 · 2020: 298 · 2019: 246 · 2018: 172 · 2017: 16
- FWCI
- 115.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Nationwide Children's Hospital
- AveXis
- Research Institute, Nationwide Children's Hospital
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- spinal muscular atrophy type 1, gene replacement therapy, adeno-associated virus vectors, SMN1, motor function, motor milestones, survival, CHOP INTEND, aminotransferase elevation, prednisolone, treatment efficacy and safety
- MeSH terms
- Dependovirus, Female, Genetic Vectors, Humans, Infant, Infant, Newborn, Infusions, Intravenous, Liver Diseases, Male, Motor Skills, Respiration, Artificial, Spinal Muscular Atrophies of Childhood, Genetic Therapy, Cohort Studies, Nutritional Support, Disease-Free Survival, Survival of Motor Neuron 1 Protein, Historically Controlled Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.